{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Left eye, no change/improved vision, n=88,94,24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Left eye, possible worsened vision, n=88,94,24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Left eye, definite worsened vision, n=88,94,24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"title":"Right eye, no change/improved vision, n=87,93,23"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"title":"Right eye, possible worsened vision, n=87,93,23"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"title":"Right eye, definite worsened vision, n=87,93,23"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. BCVA score was assessed individually for each eye. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from Baseline \\<0.12 Logarithm of the Minimum Angle of Resolution (logMAR) score; a possible worsened vision was defined as a change from Baseline \\>=0.12 to \\<0.3 logMAR score; a definite worsened vision was defined as a change from Baseline \\>=0.3 logMAR score. Data for worst-case change from Baseline is presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"},{"description":"Participants were administered lyophilized powder (100 mg/vial in a single use vial) at a dose of 3.4 mg/kg GSK2857916 given IV for a maximum of 35 cycles (1 cycle= 21 days). Lyophilized powder was reconstituted using water for injection.","id":"OG002","title":"Main Study: GSK2857916 3.4 mg/kg (Lyophilized)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and Up to 186 weeks","title":"Number of Participants With Change From Baseline in Best Corrected Visual Acuity (BCVA) Test Scores","type":"SECONDARY","unitOfMeasure":"Participants"}